Compare iShares MSCI Japan ETF (EWJ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Japan ETF trades at $97.86 (market cap $23.87B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares MSCI Japan ETF is far larger — about 2.4× State Street SPDR S&P Biotech ETF's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EWJ | XBI | |
|---|---|---|
Market Cap | $23.87B | $10.11B |
Volume | 5,412,820 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $99.32 | $169.55 |
52-Week Low | $78.36 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32, down 1.02% on the day. Technical indicators show a neutral overall signal with mixed moving averages and oscillators. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes amid fiscal stimulus concerns. The ETF remains positioned within a tight trading range between $96 support and $99 resistance levels.
Outlook remains cautious as Japan faces monetary tightening headwinds while maintaining fiscal stimulus. Investment opportunity exists in Japan's AI and semiconductor exposure, though currency volatility and rising bond yields present near-term risks. The neutral technical stance suggests limited directional momentum pending clearer policy signals from Japanese authorities.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
